Thromboxane A2 receptor (TBXA2R) is a G protein-coupled receptor (GPCR) that plays a critical role in mediating the effects of thromboxane A2 (TXA2), a lipid mediator involved in platelet aggregation, vasoconstriction, and inflammation. TBXA2R is expressed in various tissues, including platelets, vascular smooth muscle cells, and immune cells. Its activation triggers intracellular signaling pathways, such as phospholipase C (PLC) activation and calcium mobilization, contributing to thrombotic and inflammatory responses.
TBXA2R antibodies are immunological tools designed to detect, quantify, or modulate the receptor's activity. These antibodies are widely used in research to study TBXA2R expression, localization, and function in physiological and pathological contexts, such as cardiovascular diseases (e.g., atherosclerosis, thrombosis), asthma, and cancer. Polyclonal or monoclonal antibodies targeting specific epitopes of TBXA2R enable techniques like Western blotting, immunohistochemistry, and flow cytometry. Additionally, neutralizing antibodies may block receptor-ligand interactions, offering insights into TXA2-mediated signaling or therapeutic potential.
Dysregulation of TBXA2R signaling is linked to pro-thrombotic states and chronic inflammation. Genetic variants of TBXA2R have been associated with altered receptor activity and disease susceptibility. Antibodies against TBXA2R also aid in evaluating drug candidates, such as receptor antagonists (e.g., terutroban), developed to inhibit pathological thrombosis while preserving hemostasis. Overall, TBXA2R antibodies serve as essential reagents for unraveling the receptor's role in health and disease and advancing targeted therapies.